Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Outpatient
18 years of age or older at Visit 1
Diagnosis of Asthma
Male or eligible Female
Pre-bronchodilator FEV1 of 40-80% of the predicted normal value at Visit 1
Demonstrated reversibility by ≥12% and ≥200mL of FEV1 within 40 minutes following albuterol at Visit 1
A need for regular controller therapy (i.e., inhaled corticosteroids alone or in combination with a long-acting beta-agonist, or leukotriene modifier etc.,) for a minimum of 8 weeks prior to Visit 1.
You may not be if
History of Life threatening asthma
Respiratory infection not resolved
Asthma exacerbation
Concurrent respiratory disease
Current Smokers
Other diseases that are uncontrolled disease or disease state that, in the opinion of the investigator, would put the safety of the patient at risk through study participation or would confound the interpretation of the efficacy results if the condition/disease exacerbated during the study
A positive Hepatitis B surface antigen or positive Hepatitis C antibody and/or HIV
Visual clinical evidence of oropharyngeal candidiasis
Drug or milk protein allergies
Concomitant medications affecting course of asthma
Use of any other investigational medication within 30 days or 5 drug half-lives (whichever is longer)
Previous use of GSK573719
Any disease preventing use of anticholinergics
Any condition that impairs compliance with study protocol including visit schedule and completion of daily diaries
Any subject with a history of alcohol or substance abuse
